These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 2881450

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Mechanism of PLG (L-prolyl-L-leucyl-glycinamide) in treating Parkinson's disease].
    Pan JB.
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):205-8. PubMed ID: 2866940
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Brain enkephalin receptors in Parkinson's disease.
    Rinne UK, Rinne JK, Rinne JO, Laakso K, Tenovuo O, Lönnberg P, Koskinen V.
    J Neural Transm Suppl; 1983 Aug; 19():163-71. PubMed ID: 6321647
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM, Delville Y, Schallert T.
    Behav Brain Res; 2005 Jan 30; 156(2):201-13. PubMed ID: 15582106
    [Abstract] [Full Text] [Related]

  • 10. Development of new pharmacological approaches in Parkinson's disease.
    Carlsson A.
    Adv Neurol; 1987 Jan 30; 45():513-8. PubMed ID: 3493631
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G, Ozekmekçi S, Apaydin H, Delil S, Erginöz E.
    Clin Neurol Neurosurg; 2006 Dec 30; 108(8):726-32. PubMed ID: 16564615
    [Abstract] [Full Text] [Related]

  • 13. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr 30; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Case studies in the advancement of Parkinson's disease.
    Frei K, Truong DD, Wolters E.
    CNS Spectr; 2008 Dec 30; 13(12 Suppl 18):1-6. PubMed ID: 19179948
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R, Koller WC.
    Adv Neurol; 1996 Dec 30; 69():487-91. PubMed ID: 8615169
    [No Abstract] [Full Text] [Related]

  • 19. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
    Nakao N, Shintani-Mizushima A, Kakishita K, Itakura T.
    Exp Neurol; 2004 Jul 30; 188(1):65-73. PubMed ID: 15191803
    [Abstract] [Full Text] [Related]

  • 20. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
    Priano L, Albani G, Brioschi A, Calderoni S, Lopiano L, Rizzone M, Cavalli R, Gasco MR, Scaglione F, Fraschini F, Bergamasco B, Mauro A.
    Mov Disord; 2004 Aug 30; 19(8):937-42. PubMed ID: 15300660
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.